STARStrides Pharma Science Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Profit growth: 54.4% YoY
- • ROE: 20.0%
- • Debt/Equity: 0.56
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 34
- • RSI Oversold Reversal signal (setup quality 62%)
Bull case
- • Profit growth: 54.4% YoY
- • ROE: 20.0%
- • Debt/Equity: 0.56
- • Price vs SMA200: above
Bear case
- • Promoter holding: 30.8%
- • Dividend yield: 0.00%
- • RSI: 39
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Promoter holding: 30.8%
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹38.15). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.